Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Department of Anesthesiology, Xuzhou Central Hospital of Jiangsu Province, Xuzhou, China.
Minerva Anestesiol. 2020 Nov;86(11):1170-1179. doi: 10.23736/S0375-9393.20.13661-7. Epub 2020 Sep 22.
Preliminary reports suggested that presepsin was a powerful biomarker for sepsis in a general population. However, presepsin levels change with age. This study aimed to investigate the diagnostic and prognostic value of presepsin among elderly patients with sepsis in the intensive care unit (ICU).
A total of 142 elderly patients were enrolled and assorted into three groups: non-infection, infection, and sepsis. Blood samples were collected on days 1, 3 and 7 during the first week of ICU stay for presepsin measurement. Diagnostic and prognostic utilities were tested by receiver operating characteristic, cutoff levels, Kaplan Meier survival curves and hazard ratios.
The presepsin level on days 1 and 3 were significantly higher in sepsis compared with infection (P<0.01) and non-infection (P<0.01). The diagnostic area under the curve (AUC) of presepsin was comparable to that of procalcitonin (P>0.05) and higher than that of C-reactive protein or interleukin 6 (P<0.05) on days 1 and 3. In AUC and Kaplan-Meier survival curves, presepsin on day 3 showed a significant prognostic value for 30-day mortality but was not superior to other biomarkers.
The presepsin level was significantly higher in elderly patients with sepsis compared with the non-infection and infection groups. Presepsin has a reliable early diagnostic ability for sepsis comparable to that of PCT. However, it cannot be defined as a perfect biomarker for prognosis of 30-day mortality in elderly patients. An overall and continual assessment of all the clinical indexes for sepsis during the course of the disease is necessary.
初步报告表明,降钙素原前体(presepsin)在一般人群中是脓毒症的有力生物标志物。然而,降钙素原前体水平随年龄变化而变化。本研究旨在探讨降钙素原前体在重症监护病房(ICU)老年脓毒症患者中的诊断和预后价值。
共纳入 142 例老年患者,并分为三组:非感染、感染和脓毒症。在 ICU 入住的第一周内,每天在第 1、3 和 7 天采集血样进行降钙素原前体测量。通过接受者操作特征曲线、截断值、Kaplan-Meier 生存曲线和风险比来测试诊断和预后的效用。
脓毒症患者第 1 天和第 3 天的降钙素原前体水平明显高于感染(P<0.01)和非感染(P<0.01)。降钙素原前体的诊断曲线下面积(AUC)在第 1 天和第 3 天与降钙素原(P>0.05)相当,高于 C 反应蛋白或白细胞介素 6(P<0.05)。在 AUC 和 Kaplan-Meier 生存曲线中,第 3 天的降钙素原前体对 30 天死亡率具有显著的预后价值,但并不优于其他生物标志物。
与非感染和感染组相比,老年脓毒症患者的降钙素原前体水平明显升高。降钙素原前体对脓毒症具有可靠的早期诊断能力,与 PCT 相当。然而,它不能被定义为老年患者 30 天死亡率预后的完美生物标志物。在疾病过程中,需要对所有脓毒症的临床指标进行全面和持续的评估。